Drugs / DC05F01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06873542 | Jul → Dec 2022 | cancer | Heronova Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06873555 | Sep 2024 → Aug 2026 overdue | ovarian cancer, small cell lung carcinoma | Heronova Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC05F01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06873555 ↗ |
| Route | Oral | “All enrolled subjects will receive DC05F01 orally.” NCT06873542 ↗ |